[go: up one dir, main page]

RU95114740A - Peptides - Google Patents

Peptides

Info

Publication number
RU95114740A
RU95114740A RU95114740/04A RU95114740A RU95114740A RU 95114740 A RU95114740 A RU 95114740A RU 95114740/04 A RU95114740/04 A RU 95114740/04A RU 95114740 A RU95114740 A RU 95114740A RU 95114740 A RU95114740 A RU 95114740A
Authority
RU
Russia
Prior art keywords
compound
formula
complex
radionuclide
pharmaceutically acceptable
Prior art date
Application number
RU95114740/04A
Other languages
Russian (ru)
Other versions
RU2156774C2 (en
Inventor
Райнер Альберт
Питер СМИТ-ДЖОНС
Гизберт ВЕКБЕКЕР
Кристиан БРУНЗ
Барбара ШТОЛЬЦ
Original Assignee
Сандоз Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9417873A external-priority patent/GB9417873D0/en
Application filed by Сандоз Лтд. filed Critical Сандоз Лтд.
Publication of RU95114740A publication Critical patent/RU95114740A/en
Application granted granted Critical
Publication of RU2156774C2 publication Critical patent/RU2156774C2/en

Links

Claims (13)

1. Соединение формулы I
Figure 00000001

где М является катионом;
А является Рhе или Туr,
в свободной форме, в форме соли или комплекса с радионуклидом.1. The compound of formula I
Figure 00000001

where M is a cation;
A is Phe or Tur,
in free form, in salt form or complex with a radionuclide. 2. Соединение по п. 1, отличающееся тем, что А является Туr. 2. The compound according to claim 1, characterized in that A is Tu. 3. Соединение по пп. 1 и 2, отличающееся тем, что указанное соединение является комплексом с 90Y.3. Connection on PP. 1 and 2, characterized in that the compound is a complex with 90 Y. 4. Соединение по пп. 1 и 2, отличающееся тем, что указанное соединение является комплексом с 161Tb.4. Connection on PP. 1 and 2, characterized in that the compound is a complex with 161 Tb. 5. Соединение по пп. 1-4, отличающееся тем, что М является Н+.5. Connection on PP. 1-4, characterized in that M is H + . 6. Радиофармацевтическое средство, отличающееся тем, что оно представляет собой соединение формулы I по п. 1 в виде комплекса с радионуклидом или его фармацевтически приемлемой соли. 6. Radiopharmaceutical agent, characterized in that it is a compound of formula I according to claim 1 in the form of a complex with a radionuclide or its pharmaceutically acceptable salt. 7. Способ лечения опухолей и метастазов, положительных по соматостатиновым рецепторам, отличающийся тем, что для лечения используют соединение формулы I по п. 1. 7. A method of treating tumors and metastases positive for somatostatin receptors, characterized in that the treatment uses the compound of formula I according to claim 1. 8. Способ изготовления радиофармацевтического состава, отличающийся тем, что для изготовления указанного состава используют соединение формулы I по п. 1 или его фармацевтически приемлемые соли. 8. A method of manufacturing a radiopharmaceutical composition, characterized in that for the manufacture of the specified composition using the compound of formula I under item 1 or its pharmaceutically acceptable salts. 9. Фармацевтический состав, отличающийся тем, что он содержит соединение формулы I по пп. 1-5 или его фармацевтически приемлемую соль вместе с одним или несколькими фармацевтически приемлемыми носителями или растворителями. 9. Pharmaceutical composition, characterized in that it contains a compound of formula I on PP. 1-5 or its pharmaceutically acceptable salt together with one or more pharmaceutically acceptable carriers or solvents. 10. Состав по п. 9, отличающийся тем, что он дополнительно содержит стабилизатор. 10. The composition according to p. 9, characterized in that it additionally contains a stabilizer. 11. Состав по п. 10, отличающийся тем, что стабилизатор выбран из группы, состоящей из сывороточного альбумина, аскорбиновой кислоты, ретинола, гентизиновой кислоты или их производных и аминокислотного раствора. 11. The composition according to p. 10, characterized in that the stabilizer is selected from the group consisting of serum albumin, ascorbic acid, retinol, gentisic acid or their derivatives and amino acid solution. 12. Способ образования комплекса с радионуклидом соединения формулы I по п. 1, при котором соединение формулы I подвергают взаимодействию с образующим радионуклид соединением при температуре от 60 до 120oС возможно в присутствии стабилизатора.12. A method of forming a complex with a radionuclide of a compound of formula I according to claim 1, wherein the compound of formula I is reacted with the compound forming the radionuclide at a temperature of from 60 to 120 o C possible in the presence of a stabilizer. 13. Терапевтический набор для применения при лечении опухолевой инвазивности или симптомов, ассоциированных с опухолевым ростом, отличающийся тем, что он включает фармацевтический состав, содержащий соединение формулы I в виде комплекса с радионуклидом, или его фармацевтически приемлемую соль и, кроме того, включает по меньшей мере один фармацевтический состав, содержащий цитостатический агент. 13. Therapeutic kit for use in the treatment of tumor invasiveness or symptoms associated with tumor growth, characterized in that it includes a pharmaceutical composition containing the compound of formula I in the form of a complex with a radionuclide, or its pharmaceutically acceptable salt and, in addition, includes at least at least one pharmaceutical formulation containing a cytostatic agent.
RU95114740/04A 1994-09-06 1995-09-04 Somastatinic peptides, radiopharmaceutical agent, method of treating tumors, and pharmaceutical composition RU2156774C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9417873.8 1994-09-06
GB9417873A GB9417873D0 (en) 1994-09-06 1994-09-06 Organic compounds

Publications (2)

Publication Number Publication Date
RU95114740A true RU95114740A (en) 1997-08-27
RU2156774C2 RU2156774C2 (en) 2000-09-27

Family

ID=10760870

Family Applications (1)

Application Number Title Priority Date Filing Date
RU95114740/04A RU2156774C2 (en) 1994-09-06 1995-09-04 Somastatinic peptides, radiopharmaceutical agent, method of treating tumors, and pharmaceutical composition

Country Status (31)

Country Link
US (2) US6183721B1 (en)
EP (1) EP0714911B1 (en)
JP (1) JP3054346B2 (en)
KR (1) KR100364111B1 (en)
CN (1) CN1185252C (en)
AT (1) ATE199561T1 (en)
AU (1) AU703057B2 (en)
BR (1) BR9503936A (en)
CA (1) CA2157530C (en)
CO (1) CO4410344A1 (en)
CZ (1) CZ287012B6 (en)
DE (1) DE69520256T2 (en)
DK (1) DK0714911T3 (en)
ES (1) ES2157309T3 (en)
FI (1) FI117424B (en)
GB (1) GB9417873D0 (en)
GR (1) GR3035997T3 (en)
HU (1) HU218284B (en)
IL (1) IL115154A (en)
NO (1) NO316569B1 (en)
NZ (1) NZ272919A (en)
PE (1) PE41496A1 (en)
PL (1) PL182434B1 (en)
PT (1) PT714911E (en)
RU (1) RU2156774C2 (en)
SG (1) SG50356A1 (en)
SI (1) SI0714911T1 (en)
SK (1) SK283774B6 (en)
TR (1) TR199501094A2 (en)
TW (1) TW387898B (en)
ZA (1) ZA957475B (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9417873D0 (en) * 1994-09-06 1994-10-26 Sandoz Ltd Organic compounds
AT405906B (en) * 1997-03-14 1999-12-27 Irene Dr Virgolini RADIO-MARKED SOMATOSTATIN RECEPTOR LIGANDS FOR DIAGNOSIS AND THERAPY
US6358491B1 (en) 1999-08-27 2002-03-19 Berlex Laboratories, Inc. Somatostatin analogs
LT2762140T (en) 2001-02-19 2017-06-26 Novartis Ag Treatment of solid brain tumours with a rapamycin derivative
MXPA03007595A (en) * 2001-02-26 2003-12-04 Bristol Myers Squibb Pharma Co Ascorbic acid analogs for metalloradiopharmaceuticals.
AU2002305845B2 (en) * 2001-06-08 2006-03-30 Ipsen Pharma S.A.S. Somatostatin-dopamine chimeric analogs
ITMI20011708A1 (en) * 2001-08-03 2003-02-03 Bracco Imaging Spa CONJUGATES OF PEPTIDES, THEIR DERIVATIVES WITH METALLIC COMPLEXES AND USE FOR DIAGNOSTIC INVESTIGATION THROUGH IMAGING FOR MAGNETIC RESONANCE (M
EP1530482B9 (en) 2002-07-18 2014-04-16 Helix Biopharma Corp. Use of urease for inhibiting cancer cell growth
EP1610805A2 (en) * 2003-03-10 2006-01-04 Biogen Idec Inc. Thiol-mediated drug attachment to targeting peptides
KR20070034512A (en) 2004-06-18 2007-03-28 암브룩스, 인코포레이티드 New Antigen-Binding Polypeptides and Uses thereof
JP2008520616A (en) * 2004-11-24 2008-06-19 アプラーゲン ゲゼルシャフト ミット ベシュレンクテル ハフツング Solid phase peptide synthesis and purification method
CA2699394C (en) 2007-09-17 2020-03-24 The Regents Of The University Of California Internalizing human monoclonal antibodies targeting prostate cancer cells in situ
CN105388287A (en) 2011-03-11 2016-03-09 内布拉斯加大学董事委员会 Biomarker for coronary artery disease
US9480759B2 (en) 2012-11-21 2016-11-01 Serene, Llc Tin-117m somatostatin receptor binding compounds and methods
CN103275189B (en) * 2013-06-06 2014-08-06 深圳翰宇药业股份有限公司 Cracking liquid for peptide resin, and application thereof in synthesizing somatostatin by solid phase cracking
MY194484A (en) * 2013-10-18 2022-11-30 Deutsches Krebsforsch Labeled Inhibitors of Prostate Specific Membrane Antigen (PSMA), Their use as Imaging Agents and Pharmaceutical Agents for the Treatment of Prostate Cancer
FI3383920T3 (en) 2015-11-30 2024-04-10 Univ California Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen
EP4529966A3 (en) 2016-08-29 2025-06-18 Fred Hutchinson Cancer Center Chelating platform for delivery of radionuclides
EP3538551A4 (en) 2016-11-10 2020-11-11 Fortis Therapeutics, Inc. Cd46-specific effector cells and uses thereof
DK3568205T3 (en) 2017-01-12 2023-10-09 Radiomedix Inc Treatment of cancer cells overexpressing somatostatin receptors using radioisotope-chelated ocreotide derivatives
TW202015744A (en) 2018-06-21 2020-05-01 法商艾普森藥品公司 Composition containing a somatostatin analogue for radiopharmaceutical use
SG11202012377QA (en) * 2018-06-21 2021-01-28 Ipsen Pharma Sas Composition containing a somatostatin analogue for radiopharmaceutical use
US10596276B2 (en) 2018-07-25 2020-03-24 Advanced Accelerator Applications (Italy) S.R.L. Stable, concentrated radionuclide complex solutions
US10596278B2 (en) 2018-07-25 2020-03-24 Advanced Accelerator Applications (Italy) S.R.L. Stable, concentrated radionuclide complex solutions
TW202517302A (en) 2018-07-25 2025-05-01 法商高級催化劑應用品有限公司 Stable, concentrated radionuclide complex solutions
WO2020236808A1 (en) 2019-05-20 2020-11-26 Endocyte, Inc. Methods for preparing psma conjugates
IL300528A (en) 2020-08-07 2023-04-01 Fortis Therapeutics Inc Immunoconjugates targeting cd46 and methods of use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4725577A (en) * 1985-04-25 1988-02-16 Administrators Of The Tulane Educational Fund Biologically active lysine containing octapeptides
US5006643A (en) 1987-06-24 1991-04-09 The Dow Chemical Company Process for preparing isothiocyanato functionalized metal complexes
DE3728600A1 (en) 1987-08-27 1989-03-09 Hoechst Ag METHOD FOR MARKING SUBSTANCES WITH TECHNETIUM OR RHENIUM
JPH0720989B2 (en) * 1988-05-25 1995-03-08 アメリカ合衆国 Macrocyclic chelate conjugates and diagnostic test methods
GB9111199D0 (en) * 1991-05-23 1991-07-17 Sandoz Ltd Improvements in or relating to organic compounds
MY106120A (en) * 1988-12-05 1995-03-31 Novartis Ag Peptide derivatives.
DE69026387T2 (en) 1989-09-29 1996-11-28 Neorx Corp., Seattle, Wash. REDUCTION OF NON-TARGET-SPECIFIC RETENTION OF IMMUNOCONJUGATES AND THEIR METABOLITES
AU3967593A (en) * 1992-03-25 1993-10-21 Mallinckrodt Medical, Inc. Method of intraoperatively detecting and locating tumoral tissues
US5650134A (en) * 1993-01-12 1997-07-22 Novartis Ag (Formerly Sandoz Ltd.) Peptides
NZ250653A (en) * 1993-01-12 1995-12-21 Sandoz Ltd Somatostatin derivatives and pharmaceutical or diagnostic imaging compositions
WO1995019187A1 (en) * 1994-01-12 1995-07-20 Amersham International Plc Biological targeting agents
GB9417873D0 (en) * 1994-09-06 1994-10-26 Sandoz Ltd Organic compounds

Similar Documents

Publication Publication Date Title
RU95114740A (en) Peptides
JP3036602B2 (en) Technetium-99m labeled peptide for imaging
JP2954354B2 (en) Technetium-99m labeled peptide for imaging
CA2111863C (en) Technetium-99m labeled peptides for imaging
US5753205A (en) Radiolabelled peptide compounds
KR960010683A (en) Somatostatin peptide, its preparation and pharmaceutical composition containing the same
AU2020262961B2 (en) Prostate-specific membrane antigen (PSMA) inhibitors as diagnostic and radionuclide therapeutic agents
JPH06503352A (en) Technetium-99m labeled polypeptide for imaging
JPS59104377A (en) Amino acid thiolactone
RU2006122853A (en) DIARYM UREA DERIVATIVES FOR TREATMENT OF DISEASES DEPENDING ON PROTEINKINASE
IE67637B1 (en) Labeled Polypeptide Derivatives
KR920008065A (en) Peptide Compounds, Methods For Making Them, And Pharmaceutical Compositions Containing Them
JP2000515514A (en) Analogous compounds of radiometal element binding peptides
HUP0003255A2 (en) Method for the preparation of facial metal tricarbonyl compounds and their use in the labelling of biologically active substrates
ES2892955T3 (en) Bifunctional derivatives of do2pa, chelates with metal cations and their use
ES2281927T3 (en) TETRAAZA- OR N2S2- COMPLEXANTS, AND THEIR USE IN RADIODIAGNOSIS OR IN RADIOTHERAPY.
JP2954355B2 (en) Radioisotope labeled compounds for thrombus imaging
JP2007523902A (en) Technetium-bis (heteroaryl) and rhenium-bis (heteroaryl) complexes and methods of use thereof
ES8505518A1 (en) Amino-acids derivatives, process for their preparation and their use.
EP0630264B1 (en) Ligands for improving metal chelate formation kinetics
CA2194294C (en) Complexes for use in the diagnosis of vascular diseases
ES8701185A1 (en) Metal complexes of bis-indole compounds and aqueous pharmaceutical compositions containing them
ES376688A1 (en) Benzdiazepine derivatives
EP3849956A1 (en) Fluorination method
EP0590766B1 (en) Hydroxylaryl containing aminocarboxylic acid chelating agents